Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | ESR2 | Q92731 | 7/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.41 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.39 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL900534 | 1.00 | SLC18A3 (0.50) | SLC18A3MEN1MAPTKMT2AESR2 | |
| SCHEMBL1128088 | 1.00 | SLC18A3 (0.50) | SLC18A3MEN1MAPTKMT2AESR2 | |
| Hydrochloric Acid SCHEMBL20543303 | 0.97 | SLC18A3 (0.48) | SLC18A3MEN1MAPTKMT2AESR2 | |
| SCHEMBL7923165 | 0.90 | KDM1A (0.50) | SLC18A3MEN1MAPTKMT2AESR2 | |
| SCHEMBL3484987 | 0.89 | SLC18A3 (0.52) | SLC18A3MEN1MAPTKMT2AESR2 | |
| SCHEMBL15457846 | 0.89 | SLC18A3 (0.43) | SLC18A3MEN1MAPTKMT2AESR2 | |
| SCHEMBL1064153 | 0.89 | SLC18A3 (0.56) | SLC18A3MEN1MAPTKMT2AESR2 | |
| SCHEMBL24385657 | 0.88 | SLC18A3 (0.43) | SLC18A3MEN1MAPTKMT2AESR2 | |
| SCHEMBL6906434 | 0.88 | ESR2 (0.65) | SLC18A3MEN1MAPTKMT2AESR2 | |
| SCHEMBL7752607 | 0.88 | ESR2 (0.63) | SLC18A3MEN1MAPTKMT2AESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 459 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110669058-A | Tricyclic quinolone carboxylic acid and preparation method thereof | 江西农业大学 | 2020-01-10 | — | — | CN | claimed |
| EP-2398769-A1 | NOVEL ORTHO-AMINOAMIDES FOR THE TREATMENT OF CANCER | F. Hoffmann-La Roche AG (CH) | 2011-12-28 | — | — | EP | claimed |
| US-20100216806-A1 | ORTHO AMINOAMIDES FOR THE TREATMENT OF CANCER | HOFFMANN-LA ROCHE, INC. | 2010-08-26 | — | — | US | claimed |
| WO-2010094678-A1 | NOVEL ORTHO-AMINOAMIDES FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2010-08-26 | — | — | WO | claimed |
| JP-2007523865-A | — | — | 2007-08-23 | — | — | JP | claimed |
| US-7129235-B2 | Amides useful for treating pain | ABBOTT LABORATORIES (US) | 2006-10-31 | — | — | US | claimed |
| EP-1646621-A2 | NOVEL AZAHETEROCYCLIC AMIDES USEFUL FOR TREATING PAIN | Abbott Laboratories (US) | 2006-04-19 | — | — | EP | claimed |
| US-20050080095-A1 | administering a therapeuitcally effective amount of 3'-(trifluoromethyl)-N-{4-[(trifluoromethyl)sulfonyl]phenyl}-3,6-dihydro-2H-1,2'-bipyridine-4-carboxamide; antagonists of vanilloid receptor subtype I | ABBVIE INC. | 2005-04-14 | — | — | US | claimed |
| WO-2005007642-A2 | NOVEL AZAHETEROCYCLIC AMIDES USEFUL FOR TREATING PAIN | ABBOTT LABORATORIES (US) | 2005-01-27 | — | — | WO | claimed |
| EP-0030514-B1 | ANILINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM FOR REGULATING PLANT-GROWTH | RHONE-POULENC AGROCHIMIE (FR) | 1983-08-17 | — | — | EP | claimed |
| WO-2026103887-A1 | PROLINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | 北京康辰药业股份有限公司 | 2026-05-21 | — | — | WO | disclosed |
| EP-4735422-A1 | SUBSTITUTED CYCLIC COMPOUNDS AND METHODS OF TREATING PHENYLKETONURIA AND OTHER AMINO ACIDURIAS | Sanofi (FR) | 2026-05-06 | — | — | EP | disclosed |
| EP-4695236-A1 | SUBSTITUTED PHENYL-PIPERAZINYL BASED MODULATORS FOR THE TREATMENT OF DISEASE | Soley Therapeutics, Inc. (US) | 2026-02-18 | — | — | EP | disclosed |
| EP-3623372-B1 | PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | VALO HEALTH INC (US) | 2026-02-04 | — | — | EP | disclosed |
| EP-4658651-A1 | NOVEL COMPOUNDS FOR TAU IMAGING | Eli Lilly and Company (US) | 2025-12-10 | — | — | EP | disclosed |
| US-4266056-A | FUNGICIDES, BACTERICIDES | ZOECON CORPORATION (US) | 1981-05-05 | — | — | US | disclosed |
| WO-1981000565-A1 | 2-(2-CHLORO-4-CYCLOPROPYL-PHENYL-IMINO)-IMIDAZOLIDINE,ACID ADDITION SALTS THEREOF,MEDICAMENTS BASED ON SUCH COMPOUNDS AND PREPARATION PROCESS THEREOF | BOEHRINGER SOHN INGELHEIM (DE) | 1981-03-05 | — | — | WO | disclosed |
| US-4243819-A | Substituted amino acids | ZOECON CORPORATION (US) | 1981-01-06 | — | — | US | disclosed |
| US-4233055-A | Quaternary ammonioalkanecarboxylic acid anilides as plant growth influencing agents | CIBA-GEIGY CORPORATION (US) | 1980-11-11 | — | — | US | disclosed |
| US-4141718-A | ANTIGROWTH AGENTS FOR PLANTS | CIBA-GEIGY CORPORATION (US) | 1979-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216806-A1 | ORTHO AMINOAMIDES FOR THE TREATMENT OF CANCER | HDAC5, HDAC1, HDAC4 | SLC18A3 3272/4885MEN1 4289/4885MAPT 2088/4885 |
| US-20050080095-A1 | administering a therapeuitcally effective amount of 3'-(trifluoromethyl)-N-{4-[(trifluoromethyl)sulfonyl]phenyl}-3,6-dihydro-2H-1,2'-bipyridine-4-carboxamide; antagonists of vanilloid receptor subtype I | TRPV1, OPRL1, TRPV6 | SLC18A3 722/4885MEN1 4321/4885MAPT 4422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.